Goodwin Biotechnology, Inc. has signed a development and manufacturing agreement with a multinational biopharmaceutical client, under which Goodwin will develop the process to manufacture a therapeutic monoclonal antibody conjugate for diagnostic imaging purposes. The product will be manufactured under cGMP conditions as a kit for radio-labeling for use in clinical trials. Terms of the agreement were not disclosed. “This project will allow us to utilize our extensive experience and expe...